Chemical company Solvay is investing over EUR 10m to double the production capacity for specialty fluorinated aliphatic derivatives at its plant in Salindres, France. The expansion is in response to growing demand in strategic markets such as energy storage, electronics and pharmaceuticals. The first additional volumes will be available this month. The increased capacity will allow Solvay to meet the expanding requirements of electronic applications, the battery market and the pharmaceuticals market. The expansion will strengthen the Salindres plant's role as a major production site for innovative fluorinated aliphatic derivatives.
Solvay announced today it is doubling the production capacity for specialty fluorinated aliphatic derivatives at its plant in Salindres, France, to keep up with the growing demand in strategic markets, such as energy storage, electronics and pharmaceuticals. The Group is investing over EUR 10 million in the plant to double the capacity of the fluorinated aliphatic derivatives production line. The project’s first stage is currently underway and the first additional volumes will be available this month.
The Group decided to double production capacity for triflic acid and triflic anhydride (TA, TAA), as well as for Lithium bis(trifluoromethanesulfonyl)imide (LiTFSI), to meet the rapidly expanding requirements of electronic applications (such as antistatic applications for flat screens, ionic liquids and liquid crystals), the battery market (for automobiles and computers) and the pharmaceuticals market.
“This capacity expansion is strengthening the role of our Salindres plant as a major production site for innovative fluorinated aliphatic derivatives,” commented Alessandro Chiovato, General Manager of the Crop Protection, Health & Electronics business at Solvay's Global Business Unit Rhodia Aroma Performance. “It will bring us in a better position to support the growth of our customers in all regions,” he added.